Company Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Pharmaceuticals

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
3.63 USD -2.16% Intraday chart for Lexaria Bioscience Corp. +5.52% +190.40%

Business Summary

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Number of employees: 5

Sales per Business

USD in Million2022Weight2023Weight Delta
Intellectual Property Licensing
64.9 %
0 21.4 % 0 64.9 % +169.06%
Business-to-business Product
19.5 %
0 44.4 % 0 19.5 % -61.07%
Research & Development
15.6 %
0 21.5 % 0 15.6 % -35.69%

Sales per region

USD in Million2022Weight2023Weight Delta
United States and Canada
100.0 %
0 100.0 % 0 100.0 % -11.43%

Managers

Managers TitleAgeSince
Chief Executive Officer 62 06-10-25
President 53 15-04-14
Investor Relations Contact - 21-04-30
General Counsel - 18-12-31

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 62 06-10-25
Director/Board Member 70 11-07-07
Director/Board Member 74 21-01-13
President 53 15-04-14
Director/Board Member 76 15-09-15
Director/Board Member 63 22-09-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 12,671,042 11,097,355 ( 87.58 %) 0 87.58 %

Shareholders

NameEquities%Valuation
Invenomic Capital Management LP
5.996 %
731,981 5.996 % 3 M $
527,955 4.325 % 2 M $
480,000 3.932 % 2 M $
Cowen & Co. LLC
2.100 %
256,327 2.100 % 884 328 $
Waystone Fund Management (IE) Ltd.
0.5250 %
64,093 0.5250 % 221 121 $
54,075 0.4429 % 186 559 $
Geode Capital Management LLC
0.4390 %
53,592 0.4390 % 184 892 $
Vanguard Group, Inc. (Subfiler)
0.3788 %
46,241 0.3788 % 159 531 $
Citadel Securities GP LLC
0.3506 %
42,802 0.3506 % 147 667 $
13,191 0.1081 % 45 509 $
NameEquities%Valuation
Boothbay Fund Management LLC
-
78,950 - 63 160 $
CVI Holdings LLC
-
41,651 - 33 321 $

Company contact information

Lexaria Bioscience Corp.

740 McCurdy Road Suite 100

V1X 2P7, Kelowna

+

http://www.lexariabioscience.com
address Lexaria Bioscience Corp.(LEXX)

Sales per Business

Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.63 USD
Average target price
11 USD
Spread / Average Target
+203.03%
Consensus